




RealRate

PHARMACEUTICAL 2018

VYNE Therapeutics Inc.
Rank 158 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

VYNE Therapeutics Inc.
Rank 158 of 349



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 184% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is -149%, being 129% points above the market average of -278%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 63,861 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 7,817 |
| Liabilities, Non-Current | 22 |
| Other Assets | 2,978 |
| Other Compr. Net Income | -25 |
| Other Expenses | 0 |
| Other Liabilities | 6,735 |
| Other Net Income | 5,099 |
| Property and Equipment | 28 |
| Research and Development | 29,007 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 5,168 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 66,867 |
| Liabilities | 14,574 |
| Expenses | 34,175 |
| Stockholders Equity | 52,293 |
| Net Income | -29,076 |
| Comprehensive Net Income | -29,088 |
| Economic Capital Ratio | -149% |

